HMGB1 (High-Mobility Group Box-1) is a nuclear protein that acts as an architectural chromatin-binding factor involved in the maintenance of nucleosome structure and regulation of gene transcription. It can be released into the extracellular milieu from immune and non-immune cells in response to various stimuli. Extracellular HMGB1 contributes to the pathogenesis of numerous chronic inflammatory and autoimmune diseases, including sepsis, rheumatoid arthritis, atherosclerosis, chronic kidney disease, systemic lupus erythematosus (SLE), as well as cancer pathogenesis. Interaction of released HMGB1 with the cell-surface receptor for advanced glycation end products (RAGE) is one of the main signaling pathways triggering these diseases. It has been also demonstrated that the inhibition of the HMGB1–RAGE interaction represents a promising approach for the modulation of the inflammatory and tumor-facilitating activity of HMGB1.
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies / Musumeci, Domenica; Giovanni N., Roviello; Montesarchio, Daniela. - In: PHARMACOLOGY & THERAPEUTICS. - ISSN 0163-7258. - 141:3(2014), pp. 347-357. [10.1016/j.pharmthera.2013.11.001]
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
MUSUMECI, DOMENICA;MONTESARCHIO, DANIELA
2014
Abstract
HMGB1 (High-Mobility Group Box-1) is a nuclear protein that acts as an architectural chromatin-binding factor involved in the maintenance of nucleosome structure and regulation of gene transcription. It can be released into the extracellular milieu from immune and non-immune cells in response to various stimuli. Extracellular HMGB1 contributes to the pathogenesis of numerous chronic inflammatory and autoimmune diseases, including sepsis, rheumatoid arthritis, atherosclerosis, chronic kidney disease, systemic lupus erythematosus (SLE), as well as cancer pathogenesis. Interaction of released HMGB1 with the cell-surface receptor for advanced glycation end products (RAGE) is one of the main signaling pathways triggering these diseases. It has been also demonstrated that the inhibition of the HMGB1–RAGE interaction represents a promising approach for the modulation of the inflammatory and tumor-facilitating activity of HMGB1.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
